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Artemisinin combination therapyThe recent emergence and spread of artemisinin-resistant Plasmodium falciparum isolates is a growing concern
for global malaria-control efforts. A recent genome-wide analysis study identiﬁed two SNPs at genomic positions
MAL10-688956 and MAL13-1718319, which are linked to delayed clearance of parasites following artemisinin
combination therapy (ACT). It is expected that continuous artemisinin pressure will affect the distribution of
these SNPs. Here, we investigate the worldwide distribution of these SNPs using a large number of archived sam-
ples in order to generate baseline data from the period before the emergence of ACT resistance. The presence of
SNPs inMAL10-688956 andMAL13-1718319was assessed by nested PCR RFLP and direct DNA sequencing using
653 global P. falciparum samples obtained before the reported emergence of ACT resistance. SNPs at MAL10-
688956 and MAL13-1718319 associated with delayed parasite clearance following ACT administration were
observed in 8% and 3% of parasites, respectively, mostly in Cambodia and Thailand. Parasites harbouring both
SNPs were found in only eight (1%) isolates, all of which were from Cambodia and Thailand. Linkage disequilib-
rium was detected between MAL10-688956 and MAL13-1718319, suggesting that this SNP combination may
have been selected by ACT drug pressure. Neither of the SNPs associated with delayed parasite clearance were
observed in samples from Africa or South America. Baseline information of the geographical difference of
MAL10-688956 and MAL13-1718319 SNPs provides a solid basis for assessing whether these SNPs are selected
by artemisinin-based combination therapies.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
There were 207 million cases of malaria and 627 000 deaths due to
the disease world-wide in 2012 [1]. One of the most serious threats to
the successful control of malaria is the emergence of parasites that are
resistant to antimalarial drugs. TheWorldHealthOrganization currently
recommends artemisinin-based combination therapies (ACTs) as the
ﬁrst-line treatment for uncomplicated malaria. However, there is great
concern that artemisinin-resistant Plasmodium falciparum parasites
have emerged in the Cambodia/Thailand border region,where parasites
resistant to other antimalarial drugs also originated [2–6]. These ACT
“resistant” strains are characterized by a delay in the time it takes para-
sites to clear from the body following treatment [7].lar and Cellular Parasitology,
Bunkyo-ku, Tokyo, 113-8421,
and Ltd. This is an open access articleFor many anti-malarial drugs such as chloroquine and pyrimeth-
amine/sulfadoxine, the genetic mutations that underlie resistance
have been largely elucidated. These mutations can be used asmolecular
markers tomonitor the appearance and geographical spread of resistant
parasites. For artemisinin and its derivatives, a genetic region associated
with a delay in parasite clearance following ACT treatment was
identiﬁed in 2012 [8]. Soon after, four single nucleotide polymorphisms
(SNPs) linked to the delayed clearance phenotype were identiﬁed
on chromosomes 10, 13, and 14 [9]. Two of these, MAL10-688956
(A) and MAL13-1718319 (T), were proposed to be suitable molecular
markers for the resistance phenotype.
MAL10-688956 is located on chromosome 10 in the 3′ untranslated
region of the DNA polymerase delta catalytic subunit gene, and
MAL13-1718319 is in a RAD5 homolog. These two proteins are
thought to be involved in post-replication repair [9,10]. In particular,
RAD5 is a DNA clamp that is involved in the DNA damage tolerance
pathway that promotes the repair of discontinuities [11–13]. In
yeast, mutations in this gene have been implicated in cell cycle arrest
[13,14], and thus, a similar role may be expected in P. falciparum [15],under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Plasmodium falciparum isolates from 13 countries used in this study.
Country Area No. of
isolates
Year of sampling
Southeast Asia
Bangladesh Bandarban 112 2007
Cambodia Chumkiri, Kampot 43 2004, 2005, 2006
Thailand Tak, Kanchanaburi, Ratchaburi 50 2001-2
LaoPDR Khammouanne 17 1999
Philippines Palawan Island 34 1997
Paciﬁc Oceania
Papua New
Guinea
East Sepik 85 2002, 2003
Solomon
Islands
Guadalcanal Island 48 1995-6
Vanuatu Gaua, Santo, Pentecost,
Malakula
50 1996, 1998
Africa
Kenya Kisii 62 1998
Tanzania Ruﬁji River Delta 36 1998, 2003
Republic of
Congo
Pointe-Noire, Brazzaville,
Gamboma
40 2006
Ghana Winneba 44 2004
South America
Brazil Acre 32 1985-6, 1999,
2004-5
Total 653
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treatment.
We have previously analysed 53 travellers' malaria samples collected
from patients that had returned to Scotland from 11 African and nine
South-eastern Asia/Oceania countries. We found that two samples
harboured the delayed-clearance associated SNPs in both MAL10-
688956 and MAL13-1718319 [16]. These two isolates were obtained
from Thailand and Cambodia, the epicentre of the apparent emergence
of resistance to artemisinin as well as to other antimalarial drugs
[4,17,18]. This ﬁnding supports the notion that SNPs MAL10-688956
and MAL13-1718319 could be applicable as molecular markers for the
surveillance of artemisinin resistance.
However, the delayed-clearance associated SNPs are also found in
several P. falciparum laboratory maintained clones, e.g., V1/S, IT, 106/1,
and FCR3 (MAL10-688956-A) and V1/S and IT (MAL13-1718319-T),
which were isolated from patients from diverse geographic regions
and well before the ﬁrst reports of artemisinin resistance. This suggests
that the two proposed SNPs might be widely distributed, and their se-
lection unrelated to ACT pressure [9]. Thus, we consider that robust in-
formation on the global prevalence of these SNPs before thewidespread
implementation of ACTs would provide the baseline data necessary to
infer whether they are, indeed, reliable markers for the spread of ACT
resistance.
Here, we determine the distribution of delayed-clearance associated
SNPs MAL10-688956 and MAL13-1718319 using a large number of
P. falciparum isolates from East/West Africa, Asia, Paciﬁc Oceania and
South America. All samples were obtained before the ﬁrst report of
the emergence of artemisinin resistance [2].We report the complete ab-
sence of delayed-clearance associated SNPs in parasites collected from
South America and Africa. Delayed-clearance associated SNPs were
found singularly in a number of samples from areas outside Africa
and South America, but only parasites from Cambodia and Thailand
harboured both SNPs simultaneously.
2. Materials and methods
2.1. Study sites
Blood samples were obtained from P. falciparum-infected patients in
all age groups, unless otherwise stated, living in 13 malaria-endemic
countries as follows (Table 1):
1. Bangladesh: Samples were collected from patients infected with
P. falciparum in the Bandarban district hospital in 2007. This study
was approved by the Bangladesh Medical Research Council and
the local health regulatory body in Bandarban, Bangladesh [19].
2. Cambodia: Sampleswere collected from P. falciparum-infected indi-
viduals during a cross-sectional survey of rural villages in Chumkiri,
Kampot province, in 2004, 2005, and 2006. The studywas approved
by the National Center for Parasitology, Entomology, and Malaria
Control of Cambodia [20].
3. Thailand: Samples were collected from patients infected with
P. falciparum at town clinics located in the western border of Tak,
Kanchanaburi, and Ratchaburi provinces from 2001 to 2002.
The study was approved by the Ethics Committee of the Faculty of
Tropical Medicine, Mahidol University.
4. Lao People's Democratic Republic (Lao PDR): Sampleswere collected
from P. falciparum-infected individuals during cross-sectional
surveys of rural villages in Khammouanne province in 1999. The
study was approved by the Laos Ministry of Health [21].
5. Philippines: Samples were collected from patients infected with
P. falciparum in hospitals on Palawan Island in 1997. This study
was approved by the Palawan Provincial Health Ofﬁce [22].
6. Papua New Guinea: Samples were collected from P. falciparum-
infected individuals at villages in Dagua district, East Sepik
in 2002 and 2003. The study was approved by the NationalDepartment of Health Medical Research Advisory Committee of
Papua New Guinea.
7. Solomon Islands: Samples were collected from P. falciparum-infected
individuals during cross-sectional surveys in northeastern Guadalca-
nal Island from 1995 to 1996. The study was approved by the Ethics
Committee of the Solomon Islands for Medical Research.
8. Vanuatu: Samples were collected from P. falciparum-infected indi-
viduals during cross-sectional surveys in rural villages located on
4 islands; Gaua, Santo, Pentecost and Malakula, in 1996 and 1998.
The study was approved by the Vanuatu Department of Health
[23].
9. Kenya: Samples were collected from P. falciparum-infected individ-
uals during cross-sectional surveys at 4 villages in Kisii District in
1998. The study was approved by the Kenyan Ministry of Health
and Education [24].
10. Tanzania: Samples were collected from P. falciparum-infected
individuals during cross-sectional surveys in the Ruﬁji River Delta
in eastern coastal Tanzania in 1998 and 2003. The study was
approved by the Ethics Committee of the National Institute for
Medical Research of Tanzania [25].
11. Republic of the Congo: Samples were collected from patients with
P. falciparum in Pointe-Noire, Brazzaville, and Gamboma in 2006.
The study was approved by the Ministry of Research and Ministry
of Health of the Republic of the Congo [26].
12. Ghana: Sampleswere collected from P. falciparum-infected children
during cross-sectional surveys in 3 villages near Winneba, a west-
ern coastal region, in 2004. This studywas approved by theMinistry
of Health/Ghana Health Service.
13. Brazil: Samples were collected from P. falciparum-infected individ-
uals in the eastern part of Acre state in 1985–1986, 1999, and
2004–2005. The study protocol was approved by the ethics review
board of the Institute of Biomedical Sciences, University of São
Paulo.
All studieswere conducted before the ofﬁcial implementation of ACT
except in Cambodia and Thailand and before the ﬁrst ofﬁcial report of
artemisinin resistance [2]. Finger-prick blood samples were collected
and transferred on ﬁlter paper (ET31CHR; Whatman) in the all studied
regions except Thailand in which venous blood samples were used.
Parasite DNA was puriﬁed using a QIAamp DNA blood mini kit
(QIAGEN) or the EZ1 BioRobot™ (QIAGEN, Hilden, Germany) according
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was obtained from individual patients or their guardians and antimalarial
treatment was provided if necessary.
2.2. Determination of polymorphisms in MAL10-688956 and MAL13-
1718319
Nested polymerase chain reaction (PCR) for Plasmodium species
typingwas conducted to conﬁrm the presence of P. falciparum parasites
[27,28]. All P. falciparum positive samples were assayed for the presence
of SNPs in MAL10-688956 and MAL13-1718319 [9]. A PCR and restric-
tion fragment length polymorphism (RFLP) protocol was used as de-
scribed on the worldwide antimalarial resistance network (WWARN)
website: http://www.wwarn.org/toolkit/procedures with one modiﬁ-
cation (1.5 mMMgCl2 in the nested PCR for MAL13-1718319). Brieﬂy,
genotyping was conducted by nested PCR followed by RFLP analysis.
NsiI (New England Biolabs), which digests the ampliﬁed product
when the allele (T, non-delayed clearance associated SNP) is present
at the polymorphic site, was used for MAL10-688956. MslI (New
England Biolabs), which produces two digested products when the
allele (A, non-delayed clearance associated SNP) is present, was
used for MAL13-1718319. In all undigested samples, in order to
conﬁrm the presence of delayed-clearance associated SNP, nested PCR
amplicons were puriﬁed with ExoSAP–IT Kit (Amersham Biosciences,
Buckinghamshire, UK) and were directly sequenced (50 cycles of 95
°C for 20 s, 50 °C for 30 s, and 60 °C for 1 min) in one direction using
the reverse primer of the nested PCR (TTATATGTAATGGGTGAAAAGA
ATGTGG) with a BigDye Terminator 1.1 cycle sequencing kit in the Ap-
plied Biosystems 3500xL genetic analyzer (Life Technologies, Carlsbad,
California, U.S.).
2.3. Microsatellite analysis
Ten neutral microsatellite markers with no evidence of genetic
hitchhiking were genotyped to examine the possibility that linkage
disequilibrium is found between evolutionary neutral markers in the
Cambodian parasite population. The loci used were as follows: TA42
and TA81 (chromosome 5); TA1, TA87, and TA109 (chromosome 6);
TA60 and 2490 (chromosome 10); ARA2 (chromosome 11); and
Pfg377 and PfPK2 (chromosome 12). These markers were ampliﬁed
by semi-nested PCR using ﬂuorescent end-labelled primers as previous-
ly described [29]. Size variations of the ampliﬁed products were deter-
mined by electrophoresis on a DNA sequencer and analysed with
GeneScan software (Applied Biosystems). Samples with minor peaks
at least 50% in peak height compared to themajor peakwere considered
mixed genotype, and were excluded from the analysis.
2.4. Statistical analysis
D′ and r2 were measured to assess potential linkage disequilibrium
between delayed-clearance associated SNPs [30,31]. Linkage disequilib-
rium for all pairs of ten microsatellite loci was also examined using
Genepop version 4.1 under the following Markov chain parameters:
dememorization number = 20000), number of batches = 500, and
number of iterations per batch = 10000. The signiﬁcance of linkage
disequilibrium was assessed using the two-tailed Chi-squared test.
P b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. MAL10-688956
Among a total of 653 P. falciparum isolates, we successfully deter-
mined allele types for 637 isolates (98%) at MAL10-688956 (Fig. 1A).
The overall prevalence of the delayed-clearance associated SNP was
8% (52/637). Ten isolates (2%) were found to be dimorphic with bothT and A nucleotides present at this position, indicating a mixed infec-
tion. The delayed-clearance associated SNP was not detected in any
isolates from Africa or South America but was prevalent in Cambodia
(38%) and Thailand (26%). In both countries, ACTs were already in use
as ﬁrst-line therapy for uncomplicated malaria when the samples
were obtained. However, there were very few cases of the presence of
this delayed-clearance associated SNP in neighbouring countries, Laos
PDR (0%) and Bangladesh (2%). Notably, the unexpectedly high preva-
lence of the delayed-clearance associated SNP was observed in Paciﬁc
countries, 14% in Papua New Guinea, 18% in Vanuatu, and 2% in the
Solomon Islands. In these regions, artemisinin or its derivatives were
not implemented at the time of sampling.
3.2. MAL13-1718319
We successfully genotyped MAL13-1718319 in 637 isolates (98%)
(Fig. 1B). The delayed-clearance associated SNP (T) was observed
in only 18 isolates (3%), none of which were from Africa or South
America. This SNP was almost exclusively conﬁned to samples from
Cambodia and Thailand, with the exception of one sample from Papua
New Guinea, which harboured both alleles.
3.3. Combinations of delayed-clearance associated SNPs at MAL10-688956
and MAL13-1718319
Those samples harbouring a delayed-clearance associated SNP at
both MAL10-688956 and MAL13-1718319 are shown in Fig. 2. Isolates
with mixed alleles at either locus (n = 11) were excluded. Among
615 isolates, eight isolates (1%) harboured delayed-clearance associated
SNPs at both loci. Nearly all of these isolates (7/8) were localised in
Cambodia, and one was from Thailand.
3.4. Analysis of linkage disequilibrium
Linkage disequilibrium (non-random association) between
MAL10-688956 and MAL13-1718319 was observed only in Cambodia
(D′ = 0.5174 and r2 = 0.1629) (Table 2) with statistical signiﬁcance
(p=0.0146, chi-square test).We then assessed the existence of linkage
disequilibrium between ten putatively neutral microsatellite loci to
clarify whether the observed linkage disequilibrium was an inherent
feature of the Cambodian parasite population. Among a total of 36
Cambodian isolates, 25 showedmultiple alleles at least one microsatel-
lite locus and were excluded from this analysis (Table S1). Analysis of
linkage disequilibrium between each microsatellite locus produced 45
comparisons, but two results were not obtained because only one
allele combination was observed (Fig. S1). No linkage disequilibrium
was observed in the remaining 43 comparisons with the smallest
p value 0.18 (comparison between TA60 and TA42), which indicates
that linkage disequilibrium is not an inherent feature of the
Cambodian isolate population. Rather, the observed linkage disequilib-
rium may be produced by the selection of parasites that harbour both
delayed-clearance associated SNPs.
4. Discussion
We assessed the distribution of SNPs atMAL10-688956 andMAL13-
1718319 using a large number of archived worldwide P. falciparum
isolates prior to the reported emergence of ACT resistance [2]. Parasites
harbouring a combination of two delayed-clearance associated SNPs
(A allele in MAL10-688956 and T allele in MAL13-1718319) were
found exclusively in Thailand and Cambodia. In both countries, ACT
was already implemented when our sampling was carried out. This
may be due to the fact that there were no clear criteria for assessing
ACT ‘resistance’ until the mid-2000s [32], and thus, the potential emer-
gence of ACT-resistant parasitesmight have beenmissed at the time our
sampling was carried out. Additionally/alternatively, delayed-clearance
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Fig. 1. Geographical distribution of Plasmodium falciparum SNPs associated with delayed clearance following ACT treatment at (A) MAL10-688956 (n= 637) and (B) MAL13-1718319
(n = 637) in 13 countries is shown. At MAL10-688956, genotypes are classiﬁed delayed-clearance associated SNP (dark green), non-delayed clearance associated SNP (white), and
mixture of two SNPs (yellow-green). AtMAL13-1718319, genotypes consist of, delayed-clearance associated SNP (dark blue), non-delayed clearance associated SNP (white), andmixture
of two SNPs (light blue).
270 K. Murai et al. / Parasitology International 64 (2015) 267–273associated SNPs at MAL10-688956 and MAL13-1718319 alone may not
be sufﬁcient for the acquirement of the ‘resistance’ phenotype; rather,
these polymorphisms might be necessary prior to the attainment of
‘resistance’ throughmutation elsewhere in the genome. A similarmech-
anism is thought to be involved in the attainment of resistance to
pyrimethamine/sulfadoxine. Amino acid substitutions at position108 in the dihydrofolate reductase gene and at position 437 in
dihydropteroate synthase gene are not, in themselves, sufﬁcient to con-
fer a high degree of in vivo resistance, but they are required as an initial
step for the further acquisition of other mutations in these genes that
eventually result in pyrimethamine and sulfadoxine resistance, respec-
tively [33,34]. It is possible that resistance to artemisinin would require
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Fig. 2. Geographical distribution of allele combinations of MAL10-688956 andMAL13-1718319 in 13 countries is shown (n= 615). MAL10-688956 delayed-clearance associated SNP+
MAL13-1718319 delayed-clearance associated SNP (red), MAL10-688956 delayed-clearance associated SNP+MAL13-1718319 non-delayed clearance associated SNP (orange), MAL10-
688956 non-delayed clearance associated SNP + MAL13-1718319 delayed-clearance associated SNP (yellow) and MAL10-688956 non-delayed clearance associated SNP + MAL13-
1718319 non-delayed clearance associated SNP (white). Isolates harbouring mixed genotypes at either MAL10-688956 or MAL13-1718319 were excluded.
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one or more undetermined gene(s) that were not identiﬁed in the
previous genome-wide association study by Takala-Harrison et al. [9]
might be required for the ‘resistance’ phenotype. A recent deep
whole-genome sequencing study has indicated that linkage disequilib-
rium decayed within 1 kb [35]. Hence, as noted by the authors, the
SNP markers used for the previous genome-wide association study,
7 kb apart on average, may not be enough to detect all loci associated
with parasite clearance [9].
The delayed-clearance associated SNP combination was mainly dis-
tributed in Cambodia, and these SNPs were signiﬁcant linked. Since the
two SNPs are located on different chromosomes (10 and 13), physical
linkage does not explain the observed linkage disequilibrium. Thus,
the following two mechanisms are proposed for the observed linkage
disequilibrium: (1) low diversity within the Cambodian population,
leading to the signature of linkage disequilibriumbetweenmarkers sep-
arated by large physical distances on the genome, and (2) natural selec-
tion of a particular allele combination that has a sufﬁcient selective
advantage over others [36]. To test the former possibility, we examined
linkage disequilibrium using 10microsatellite markers that are thoughtTable 2
Linkage disequilibrium in the Plasmodium falciparum between MAL10-688956 and
MAL13-1718319 in Bangladesh, Cambodia, and Thailand.
Country n D′ r2 p valuea
Bangladesh 112 ND 0.00016 0.8491
Cambodia 37 0.5174 0.1629 0.0146
Thailand 44 0.3231 0.00561 0.6074
ND, not determined. Bold letters show the signiﬁcance (P b 0.05).
Isolates in which allele types were not determined were excluded (n = 4), and then
isolates harbouring both delayed-clearance associated SNP/non-delayed-clearance associ-
ated SNP in either MAL10-688956 or MAL13-1718319 were excluded (n = 8).
a χ2 test.to be selectively neutral. We did not ﬁnd linkage disequilibrium be-
tween any of the possible pairs of microsatellite loci, suggesting that
the observed linkage disequilibriumbetween twodelayed-clearance as-
sociated SNPs is not the result of low diversity within the Cambodian
parasite population. Hence, it is probable that the observed linkage
disequilibrium is a result of selective pressure favouring parasites
with both delayed-clearance associated SNPs. The continuous use of
artemisinin in this area is one candidate for possible selecting factors.
We found no evidence for the existence of delayed-clearance associ-
ated SNPs at either MAL10-688956 or MAL13-1718319 in Africa or
South America. All the samples from African regions were collected be-
tween 1998 and 2006, at the time period before the wide-scale imple-
mentation of artemisinin derivatives. Practically, the development of a
crediblemolecularmarker of ACT resistance is urgently required, partic-
ularly in sub-Saharan Africa. Sincemany individuals living in this region
develop protective immunity to malaria after repeated infections, this
immunity would enhance the effectiveness of antimalarial drugs [37].
As a result, these patients may respond to antimalarial drugs even
if they are infected with drug-resistant parasites [38–40] and, in
such cases, it would be impossible to monitor the emergence of
artemisinin-resistant parasites based on clinical information alone [16]
. In this regard, the absence of either delayed-clearance associated
SNPs before wide-scale implementation of artemisinin derivatives in
Africa suggests that assessment of MAL10-688956 or MAL13-1718319
may allow the detection of the emergence of artemisinin resistance
before the appearance of clinical failure cases.
The following points, however, should be further considered for
the application of MAL10-688956 and MAL13-1718319 as molecular
markers for the surveillance of the emergence of ACT resistance. In the
Paciﬁc region, the prevalence of the MAL10-688956 delayed-clearance
associated SNP was unexpectedly high, although nearly all parasites
harbored the non-delayed clearance associated SNP at MAL13-
1718319. Artemisinin combination therapies were not implemented
272 K. Murai et al. / Parasitology International 64 (2015) 267–273at the time of sampling in any of the countries considered here. Hence, it
seems likely that the MAL10-688956 delayed-clearance associated SNP
is a parasite polymorphism that exists naturally in the parasite popula-
tions of this region and was not, initially, selected by ACT pressure.
The other possibility is the migration of the MAL10-688956 delayed-
clearance associated SNP from Southeast Asia. However, since the
prevalence of this SNP was high, this may be unlikely, especially in the
absence of ACT selection pressure. Further analysis using microsatellite
alleles ﬂanking the SNP will clarify the possible migration of from the
MAL10-688956 SNP to Southeast Asia.
Recently, another artemisinin-resistance related marker,
PF3D7_1343700 kelch propeller domain (‘K13-propeller’) gene, has
been identiﬁed using whole-genome sequencing of an artemisinin-
resistant parasite line [41]. A number of SNPs (at least 17) were
described in the propeller domains of K13, some of whichmight be pre-
dictive SNPs of resistance in different geographical settings. This gene
may prove more suitable as a molecular marker for ACT-resistant
parasites than the two described here.
5. Conclusions
Parasites bearing delayed-clearance associated SNPs at bothMAL10-
688956 and MAL13-1718319 are localised to Cambodia and Thailand.
Both the delayed-clearance associated SNPs were entirely absent from
Africa or South America prior to the introduction of ACTs as ﬁrst-line
treatments formalaria in these countries. This study provides baseline in-
formation for geographical differences in the distribution of malaria par-
asites carrying delayed-clearance associated SNPs at bothMAL10-688956
andMAL13-1718319, and so lays the groundwork for developing molec-
ularmarkers formonitoring the emergence and spread of ACT resistance.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.parint.2014.11.002.
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